Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/8356
E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
Horne, Hisani N | Oh, Hannah | Sherman, Mark E | Palakal, Maya | Hewitt, Stephen M | Schmidt, Marjanka K | Milne, Roger L | Hardisson, David | Benitez, Javier CNIO | Blomqvist, Carl | Bolla, Manjeet K | Brenner, Hermann | Chang-Claude, Jenny | Cora, Renata | Couch, Fergus J | Cuk, Katarina | Devilee, Peter | Easton, Douglas F | Eccles, Diana M | Eilber, Ursula | Hartikainen, Jaana M | Heikkilä, Päivi | Holleczek, Bernd | Hooning, Maartje J | Jones, Michael | Keeman, Renske | Mannermaa, Arto | Martens, John W M | Muranen, Taru A | Nevanlinna, Heli | Olson, Janet E | Orr, Nick | Perez, Jose I A | Pharoah, Paul D P | Ruddy, Kathryn J | Saum, Kai-Uwe | Schoemaker, Minouk J | Seynaeve, Caroline | Sironen, Reijo | Smit, Vincent T H B M | Swerdlow, Anthony J | Tengström, Maria | Thomas, Abigail S | Timmermans, A Mieke | Tollenaar, Rob A E M | Troester, Melissa A | van Asperen, Christi J | van Deurzen, Carolien H M | Van Leeuwen, Flora F | Van't Veer, Laura J | García-Closas, Montserrat | Figueroa, Jonine D
Sci Rep. 2018 ;8(1):6574.
E-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97-1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06-2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
Files in this item
- E-cadherinbreasttumor _2018.pdf